Toceranib (INN[2]), sold under the brand name Palladia, is a receptor tyrosine kinase inhibitor that is used in the treatment of canine mast cell tumor also called mastocytoma.[3] It is the first medication developed specifically for the treatment of cancer in dogs.[4][5] It is used as its phosphate salt, toceranib phosphate. It was developed by SUGEN as SU11654,[6] a sister compound to sunitinib, which was later approved for human therapies. Toceranib is a tyrosine kinase inhibitor and works in two ways: by killing tumor cells and by cutting off the blood supply to the tumor.[4]

Toceranib
Ball-and-stick model of the toceranib molecule
Clinical data
Trade namesPalladia
AHFS/Drugs.comVeterinary Use
License data
Routes of
administration
By mouth
Drug classAntineoplastic agent
ATCvet code
Legal status
Legal status
Pharmacokinetic data
Bioavailability77%
Protein binding91%-93%
Elimination half-life16 h
Identifiers
  • 5-[(5Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(pyrrolidin-1-yl)ethyl]-1H-pyrrole-3-carboxamide
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
PDB ligand
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC22H25FN4O2
Molar mass396.466 g·mol−1
3D model (JSmol)
  • Fc1ccc2c(c1)/C(C(=O)N2)=C/c4c(c(C(=O)NCCN3CCCC3)c([nH]4)C)C
  • InChI=1S/C22H25FN4O2/c1-13-19(12-17-16-11-15(23)5-6-18(16)26-21(17)28)25-14(2)20(13)22(29)24-7-10-27-8-3-4-9-27/h5-6,11-12,25H,3-4,7-10H2,1-2H3,(H,24,29)(H,26,28)/b17-12-
  • Key:SRSGVKWWVXWSJT-ATVHPVEESA-N

The most common side effects include diarrhea, decrease or loss of appetite, lameness, weight loss, and blood in the stool.[4]

Veterinary uses

edit

Toceranib is indicated to treat canine cutaneous (skin-based) mast cell tumors, a type of cancer responsible for about one out of five cases of canine skin tumors.[4] It is approved to treat the tumors with or without regional lymph node involvement.[4]

References

edit
  1. ^ "Palladia EPAR". European Medicines Agency. 1 October 2009. Retrieved 1 July 2024.
  2. ^ World Health Organization (2009). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 62". WHO Drug Information. 23 (2). hdl:10665/74420.
  3. ^ London CA, Malpas PB, Wood-Follis SL, Boucher JF, Rusk AW, Rosenberg MP, et al. (June 2009). "Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision". Clinical Cancer Research. 15 (11): 3856–3865. doi:10.1158/1078-0432.CCR-08-1860. PMID 19470739.
  4. ^ a b c d e "FDA: First Drug to Treat Cancer in Dogs Approved". U.S. Food and Drug Administration (FDA) (Press release). 3 June 2009. Archived from the original on 22 July 2010. Retrieved 2 October 2021.   This article incorporates text from this source, which is in the public domain.
  5. ^ "Palladia New Animal Drug Application" (PDF). U.S. Food and Drug Administration (FDA). 22 May 2009. Archived from the original (PDF) on 16 November 2010. Retrieved 2 October 2021.
  6. ^ "In Trials for New Cancer Drugs, Family Pets Are Benefiting, Too". The New York Times. 24 November 2006. Archived from the original on 27 February 2021. Retrieved 2 October 2021.